TY - JOUR
T1 - N-acetyl S-(1,2-dichlorovinyl)-l-cysteine produces a similar toxicity to S-(1,2-dichlorovinyl)-l-cysteine in rabbit renal slices
T2 - differential transport and metabolism
AU - Wolfgang, Grushenka H.I.
AU - Jay Gandolfi, A.
AU - Stevens, James L.
AU - Brendel, Klaus
N1 - Funding Information: This study was supported by NIH Grants DK 38925 and AM 38290, Training Grant T32 ES 07091, and Johns Hopkins Center for Alternatives to Animal Testing. We thank Patricia Kime for typing the manuscript.
PY - 1989/11
Y1 - 1989/11
N2 - Renal cortical slices were used to determine the toxicity of N-acetyl S-(1,2-dichlorovinyl)-l-cysteine (N-acetyl-DCVC) as well as to investigate the transport and metabolism of S-(1,2-dichlorovinyl)-l-cysteine (DCVC) and the N-acetyl derivative. N-Acetyl-DCVC produced dose- and time-dependent decreases in intracellular K+ content and lactate dehydrogenase activity. Histopathology demonstrated an initial S3 lesion followed by a lesion inclusive of all proximal tubules. N-Acetyl-DCVC was shown to be transported via the organic anion system by its ability to inhibit PAH transport by the cells and the ability of probenecid to decrease uptake (80%) and toxicity of N-acetyl-DCVC. DCVC, in contrast, was not transported by the organic anion system, but may be transported by one or more amino acid system. N-Acetyl-DCVC must be deacetylated before undergoing metabolism by β-lyase. This process must occur since covalent binding of a 35S-labeled reactive product from N-acetyl[35S]DCVC is observed within 1 hr. Both the uptake inhibitor, probenecid, and aminooxyacetic acid (AOAA), a β-lyase inhibitor, decreased the covalent binding from N-acetyl[35S]DCVC (80 and 50%, respectively), but only AOAA inhibited the covalent binding of DCVC. AOAA also partially inhibited the toxicity of DCVC and N-acetyl-DCVC as determined by intracellular K+ content, lactate dehydrogenase activity, and histopathology. Despite the fact that a separate transport system and an additional enzymatic step (deacetylation) are required, N-acetyl-DCVC produces a lesion with similar intratubular specificity to that seen with DCVC. Therefore, the S3 specificity seen in vivo could be produced by either compound.
AB - Renal cortical slices were used to determine the toxicity of N-acetyl S-(1,2-dichlorovinyl)-l-cysteine (N-acetyl-DCVC) as well as to investigate the transport and metabolism of S-(1,2-dichlorovinyl)-l-cysteine (DCVC) and the N-acetyl derivative. N-Acetyl-DCVC produced dose- and time-dependent decreases in intracellular K+ content and lactate dehydrogenase activity. Histopathology demonstrated an initial S3 lesion followed by a lesion inclusive of all proximal tubules. N-Acetyl-DCVC was shown to be transported via the organic anion system by its ability to inhibit PAH transport by the cells and the ability of probenecid to decrease uptake (80%) and toxicity of N-acetyl-DCVC. DCVC, in contrast, was not transported by the organic anion system, but may be transported by one or more amino acid system. N-Acetyl-DCVC must be deacetylated before undergoing metabolism by β-lyase. This process must occur since covalent binding of a 35S-labeled reactive product from N-acetyl[35S]DCVC is observed within 1 hr. Both the uptake inhibitor, probenecid, and aminooxyacetic acid (AOAA), a β-lyase inhibitor, decreased the covalent binding from N-acetyl[35S]DCVC (80 and 50%, respectively), but only AOAA inhibited the covalent binding of DCVC. AOAA also partially inhibited the toxicity of DCVC and N-acetyl-DCVC as determined by intracellular K+ content, lactate dehydrogenase activity, and histopathology. Despite the fact that a separate transport system and an additional enzymatic step (deacetylation) are required, N-acetyl-DCVC produces a lesion with similar intratubular specificity to that seen with DCVC. Therefore, the S3 specificity seen in vivo could be produced by either compound.
UR - http://www.scopus.com/inward/record.url?scp=0024378682&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024378682&partnerID=8YFLogxK
U2 - 10.1016/0041-008X(89)90270-6
DO - 10.1016/0041-008X(89)90270-6
M3 - Article
C2 - 2815079
SN - 0041-008X
VL - 101
SP - 205
EP - 219
JO - Toxicology and Applied Pharmacology
JF - Toxicology and Applied Pharmacology
IS - 2
ER -